Glenmark’s innovative nasal spray gets EU marketing approval

INDIA – Glenmark Pharmaceuticals has announced that its fixed-dose combination nasal spray, Ryaltris, has received marketing approval in 13 countries across the EU and the UK, bolstering the company’s respiratory therapy line. Glenmark is a global research-led pharmaceutical company with operations in over 50 countries and a presence in generics, specialty, and over-the-counter (OTC) businesses. Glenmark’s primary therapeutic focus areas include respiratory, dermatology, and oncology. In terms of revenue, it is ranked among the top 80 Pharma & Biotech companies in the world. Ryaltris is a combination of antihistamine plus…

Read More

Cadila sells two of its brands as Glenmark bags USFDA nod for generic antibiotic cream

INDIA – Cadila Healthcare has announced that its subsidiary has inked a pact with Integrace Private Limited to sell two brands, Mifegest and Cytolog at an undisclosed amount. Zydus Healthcare Ltd, a wholly-owned subsidiary of the company, has inked the agreement with Integrace, a part of the portfolio companies of private equity firm True North. “The said transaction is expected to be completed within 30 days from the date of execution of agreement, subject to customary approvals,” Cadila Healthcare said in a regulatory filing. Meanwhile, Cadila’s competitors Glenmark Pharmaceuticals has…

Read More

Glenmark concludes post marketing surveillance (PMS) study on Favipiravir

INDIA – Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today announced the successful completion of its Post Marketing Surveillance (PMS) study on Favipiravir in India. The study commenced in July 2020 to evaluate the safety and efficacy of Favipiravir in mild to moderate COVID-19 patients, Glenmark said in a statement. Results showed no new safety signals or concerns with the use of Favipiravir, and already-known side effects like weakness, gastritis, diarrhea, vomiting among others were found to be mild in nature. The time for fever resolution was 4 days,…

Read More

Glenmark inks deal with SaNOtize to commercialize COVID-19 treatment spray in Asia

INDIA – Glenmark Pharmaceuticals has signed an agreement with Canadia’s biotech firm SaNOtize Research and Development Group to commercialize its Nitric Oxide Nasal spray (NONS) for Covid-19 treatment in India and other Asian markets. Glenmark will collaborate with SaNOtize to manufacture, market and distribute this breakthrough Nitric Oxide Nasal Spray through their exclusive long-term partnership. It expects to launch the nasal spray this year under the brand name ‘FabiSpray’ in India. ”The Phase III clinical trial for NONS is expected to be completed, followed by commercial launch under the brand…

Read More

Covaxin trials now set to be conducted on children across six hospitals as also Glenmark plans to roll out its phase 3 trials of its nasal COVID-19 treatment

INDIA – The Indian government is aggressively trying to curb the COVID -19 pandemic with the roll out of various programs across the state. Currently the state has embarked on two programs in a bid to curb the spread of the virus with the first one being conducting vaccine trials on children (Covaxin trials) and the second one involving phase 3 trials of a nasal therapy meant to cure COVID-19 symptoms. The Covaxin trials will be conducted on 175 children aged 2-6, 6-12 and 12-18 who will be given the…

Read More